Superluminal Medicines Inc.

Superluminal Medicines Inc. company information, Employees & Contact Information

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

Company Details

Employees
30
Address
15 Necco St, Lilly Gateway Labs
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Boston, Massachusetts
Looking for a particular Superluminal Medicines Inc. employee's phone or email?

Superluminal Medicines Inc. Questions

News

Superluminal Medicines Announces a Selective, Biased, MC4R Agonist is Advancing to IND-enabling Studies for the Treatment of Obesity - PR Newswire

Superluminal Medicines Announces a Selective, Biased, MC4R Agonist is Advancing to IND-enabling Studies for the Treatment of Obesity PR Newswire

Superluminal Medicines Closes $120 Million Series A Round - GlobeNewswire

Superluminal Medicines Closes $120 Million Series A Round GlobeNewswire

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics - Yahoo Finance

Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics Yahoo Finance

Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship - Business Wire

Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship Business Wire

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity - PR Newswire

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity PR Newswire

Top Superluminal Medicines Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant